2008
DOI: 10.3129/i07-190
|View full text |Cite
|
Sign up to set email alerts
|

Dalteparin in the management of recent onset central retinal vein occlusion: a comparison with acetylsalicylic acid

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
18
0

Year Published

2009
2009
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 16 publications
(18 citation statements)
references
References 23 publications
0
18
0
Order By: Relevance
“…Whereas one study administered parnaparin for three months, the other two studies used dalteparin for only 20 days. Since the latter studies reported clinical benefit in patients with central 41 but not branch RVO 38 it might be possible that a more prolonged period of anticoagulation might actually result in a benefit for patients with BRVO, as suggested by the results of the study by Ageno and co-workers. 40 This is, in our opinion, one of the most important issues yet to be determined.…”
Section: Discussionmentioning
confidence: 94%
“…Whereas one study administered parnaparin for three months, the other two studies used dalteparin for only 20 days. Since the latter studies reported clinical benefit in patients with central 41 but not branch RVO 38 it might be possible that a more prolonged period of anticoagulation might actually result in a benefit for patients with BRVO, as suggested by the results of the study by Ageno and co-workers. 40 This is, in our opinion, one of the most important issues yet to be determined.…”
Section: Discussionmentioning
confidence: 94%
“…Also in this case, no rigorous clinical data support this hypothesis. Recently, the superiority of a lowmolecular weight heparin, dalteparin, over acetylsalicylic acid used in the first 6 months of treatment, in terms of improving visual acuity and preventing iris neovascularization, has been reported [38].…”
Section: Discussionmentioning
confidence: 99%
“…LMWHs appear to have the best risk-benefit profile, in particular in comparison with aspirin, whereas no clear cut conclusions can be drawn on the potential benefits of LMWHs over no antithrombotic treatment, and it is unclear if CRVO and BRVO receive the same benefit from LMWHs. Although present evidence is weak and based on data from three small trials [45][46][47], it is the first time that we have some evidence in this field. A recent meta-analysis confirms these data [50].Thus, we suggest for our RVO patients, if diagnosed within 15 days from clinical manifestations, LMWHs at anticoagulant doses for 10-15 days followed by half dose for a total of 90 days, according to Ageno et al's protocol [45].…”
Section: Medical Treatmentmentioning
confidence: 95%
“…Recently, a systematic review of the literature has been performed by Squizzato et al [44]. The Authors selected six high-quality published studies (from 1976 to 2009) on acute treatment and secondary prevention of RVO with antithrombotic and fibrinolytic drugs ( Table 2) [45][46][47][48][49]. Only one randomised controlled trial was identified with a double-bind, double-dummy design, with the assessor of the outcome masked to the treatment group and with detailed description of withdrawal and drop-out patients [45].…”
Section: Medical Treatmentmentioning
confidence: 99%